Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

Osimertinib-Induced Lung Injury and Treatment Rechallenge: Clinical Insights From a Case Report With a Comprehensive Literature Review.

Clinical lung cancer - 1 Mar 2026

Citarella Fabrizio, Mingo Emanuele C, Fiorenti Matteo, Russano Marco, Perrone Giuseppe, La Cava Giulia, Santo Valentina, Vendittelli Alessia, Brunetti Leonardo, Saracino Cecilia, Esposito Ludovica, Malgeri Andrea, Ramella Sara, Vincenzi Bruno, Tonini Giuseppe, Cortellini Alessio

Abstract excerpt

Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) widely used in EGFR mutant non-small cell lung cancer (NSCLC). Despite a favorable safety profile, osimertinib-induced lung injury (OILI) remains a rare but clinically significant adverse event. Guidelines recommend permanent discontinuation after severe cases; the rechallenge feasibility in selected patients...

Topics

Join the communities discussing this publication.

Acrylamides
Aniline Compounds
Carcinoma, Non-Small-Cell Lung
ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Protein Kinase Inhibitors

Source

Identifiers

PMID: 41548383
DOI: 10.1016/j.cllc.2025.12.006

Genes

EGFR
MET

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Osimertinib-Induced Lung Injury and Treatment Rechallenge: Clinical Insights From a Case Report With a Comprehensive Literature Review.PMID 41548383Read ↗

Safety and efficacy of osimertinib rechallenge or continuation after pneumonitis: A multicentre retrospective cohort study.Semantic proximity Read ↗

Successful administration of low-dose almonertinib in a patient with lung adenocarcinoma after osimertinib-induced interstitial lung disease: a case report and literature review.Semantic proximity Read ↗

EGFR-TKI rechallenge in patients with EGFR-mutated non-small-cell lung cancer who progressed after first-line osimertinib treatment: A multicenter retrospective observational study.Semantic proximity Read ↗

Life-threatening pneumonitis after first-line treatment with osimertinib for primary T790M mutated non-small cell lung cancer.Semantic proximity Read ↗

Life-threatening Pneumonitis Induced by Osimertinib Monotherapy as a First-line Treatment for Epidermal Growth Factor Receptor Mutation-positive Non-small-cell Lung Cancer: A Retrospective Case-series Study.Semantic proximity Read ↗

Drug-Related Pneumonitis Induced by Osimertinib as First-Line Treatment for Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Real-World Setting.Semantic proximity Read ↗

Successful Treatment with Afatinib after Osimertinib-induced Interstitial Lung Disease in a Patient with EGFR-mutant Non-small-cell Lung Cancer.Semantic proximity Read ↗

Real-World Study of Osimertinib in Korean Patients with Epidermal Growth Factor Receptor T790M Mutation-Positive Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Adverse Events in Osimertinib Treatment for EGFR-Mutated Non-Small-Cell Lung Cancer: Unveiling Rare Life-Threatening Myelosuppression.Semantic proximity Read ↗

Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non-Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease.Semantic proximity Read ↗

Successful rechallenge twice with different EGFR-TKIs in a patient with lung adenocarcinoma after EGFR- TKI-induced grade 3 stomatitis and interstitial lung disease: a case reportSemantic proximity Read ↗

[Pulmonary manifestations induced by osimertinib].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.